Labcorp Holdings declares $0.72 quarterly dividend for 2026

Labcorp declares $0.72 per share cash dividend. Payment scheduled for December 11, 2026. Record date set for November 24, 2026.

Labcorp Holdings to acquire Myriad prenatal unit for $210 million

Labcorp Holdings agreed to acquire Myriad Genetics' prenatal health testing business for $210 million in cash plus inventory value. The acquired assets are expected to generate approximately $160 million in annual revenue in the first year. Myriad's prenatal unit saw a 16% YoY revenue decline in Q2 2026, with volumes down 9%. Labcorp expects the transaction to be slightly accretive to adjusted earnings in year one and reach average segment margins by year two. The deal is projected to close by early 2027, following Labcorp's recent $872 million BioReference Health acquisition.

Labcorp to acquire BioReference assets for $722M cash plus earnout

Labcorp acquires select BioReference Health assets for $722 million cash plus up to $150 million earnout. Total potential deal value reaches $872 million, subject to revenue adjustments and 4Kscore Test performance. Acquisition includes clinical, women's health, urology, and corrections testing businesses plus 80+ service centers. OPKO Health shifts focus to core biopharmaceuticals; shares rose nearly 8% on the announcement. Labcorp expects acquired operations to generate approximately $250 million in revenue in the first year.

Labcorp sets 5-8% revenue CAGR through 2029, reaffirms FY26 guidance

Labcorp reaffirms full-year 2026 financial guidance. Targets 5% to 8% compound annual revenue growth through 2029. Projects 8.5% to 11.5% compound annual adjusted EPS growth. Highlights strategic focus on diagnostics, biopharma, and technology.

Labcorp settles wiretapping claims with two-year tracking tech ban

Labcorp settles class action alleging wiretapping law violations in CA and PA. Agreement includes a two-year ban on tracking tech like Meta Pixel and Google Analytics. Settlement provides only injunctive relief; no monetary damages for class members. Class covers users who conducted search queries between May 1, 2021, and April 1, 2026. Objections must be postmarked by Nov. 23, 2026.

Labcorp launches next-gen Global Trial Connect to streamline clinical trials

Labcorp launches enhanced Global Trial Connect platform on August 31, 2026. Embedded kit ordering reduces manual data entry by 75%. Updates guided by input from 80+ sponsors and 100+ investigator sites. New Study Oversight Dashboard provides unified view of trial insights.